pbs_code
stringlengths 5
6
| drug
stringclasses 17
values | brand
stringclasses 30
values | formulation
stringclasses 37
values | indication
stringclasses 8
values | treatment_phase
stringclasses 57
values | streamlined_code
stringclasses 33
values | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | schedule_code
int64 4.43k
4.43k
| schedule_year
int64 2.03k
2.03k
| schedule_month
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
11489Q | Infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,429 | 2,025 | APRIL |
11489Q | Infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,429 | 2,025 | APRIL |
11489Q | Infliximab | Remicade | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,429 | 2,025 | APRIL |
11490R | Infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Subsequent continuing treatment | 14504 | true | STREAMLINED | Public | 4,429 | 2,025 | APRIL |
11490R | Infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Subsequent continuing treatment | 14504 | true | STREAMLINED | Public | 4,429 | 2,025 | APRIL |
11490R | Infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Subsequent continuing treatment | 14504 | true | STREAMLINED | Public | 4,429 | 2,025 | APRIL |
11497D | Infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,429 | 2,025 | APRIL |
11497D | Infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,429 | 2,025 | APRIL |
11497D | Infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,429 | 2,025 | APRIL |
11498E | Infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,429 | 2,025 | APRIL |
11498E | Infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,429 | 2,025 | APRIL |
11498E | Infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,429 | 2,025 | APRIL |
11514B | Infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | 9188 | true | STREAMLINED | Public | 4,429 | 2,025 | APRIL |
11514B | Infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | 9188 | true | STREAMLINED | Public | 4,429 | 2,025 | APRIL |
11515C | Infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | 9472 | true | STREAMLINED | Private | 4,429 | 2,025 | APRIL |
11515C | Infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | 9472 | true | STREAMLINED | Private | 4,429 | 2,025 | APRIL |
11516D | Golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Continuing treatment | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11516D | Golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11521J | Golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | non-radiographic axial spondyloarthritis | Continuing treatment | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11521J | Golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | non-radiographic axial spondyloarthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11538G | Golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | non-radiographic axial spondyloarthritis | Initial treatment - Initial 1 (New patient) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11538G | Golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | non-radiographic axial spondyloarthritis | Initial treatment - Initial 2 (Change or re-commencement of treatment after a break of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11538G | Golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | non-radiographic axial spondyloarthritis | Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11538G | Golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | non-radiographic axial spondyloarthritis | Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11560K | Golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial treatment - Initial 1 (New patient) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11560K | Golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial treatment - Initial 2 (Change or re-commencement of treatment after a break of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11560K | Golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11560K | Golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11565Q | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11565Q | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11565Q | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11565Q | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11567T | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11567T | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11623R | Ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11623R | Ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11623R | Ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11623R | Ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11623R | Ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | psoriatic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11623R | Ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11675L | Tofacitinib | Xeljanz | Tablet 5 mg | psoriatic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11675L | Tofacitinib | Xeljanz | Tablet 5 mg | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11684Y | Abatacept | Orencia ClickJect | Injection 125 mg in 1 mL single dose autoinjector | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11684Y | Abatacept | Orencia ClickJect | Injection 125 mg in 1 mL single dose autoinjector | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11690G | Tofacitinib | Xeljanz | Tablet 5 mg | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11690G | Tofacitinib | Xeljanz | Tablet 5 mg | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11690G | Tofacitinib | Xeljanz | Tablet 5 mg | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11690G | Tofacitinib | Xeljanz | Tablet 5 mg | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11693K | Abatacept | Orencia ClickJect | Injection 125 mg in 1 mL single dose autoinjector | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11693K | Abatacept | Orencia ClickJect | Injection 125 mg in 1 mL single dose autoinjector | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11693K | Abatacept | Orencia ClickJect | Injection 125 mg in 1 mL single dose autoinjector | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11693K | Abatacept | Orencia ClickJect | Injection 125 mg in 1 mL single dose autoinjector | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11720W | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14150 | true | STREAMLINED | Any | 4,429 | 2,025 | APRIL |
11721X | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | giant cell arteritis | Continuing treatment | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11722Y | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | giant cell arteritis | Continuing treatment | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11725D | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11725D | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11725D | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11725D | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11730J | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11730J | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Continuing Treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11734N | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11734N | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11734N | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11734N | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11741Y | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11741Y | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11741Y | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11741Y | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11742B | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14150 | true | STREAMLINED | Any | 4,429 | 2,025 | APRIL |
11743C | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | giant cell arteritis | Initial treatment | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11744D | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | giant cell arteritis | Initial treatment | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11748H | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11748H | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11748H | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11748H | Tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11750K | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11750K | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Continuing Treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11979L | Upadacitinib | Rinvoq | Tablet 15 mg | rheumatoid arthritis | First Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11979L | Upadacitinib | Rinvoq | Tablet 15 mg | rheumatoid arthritis | First Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11989B | Upadacitinib | Rinvoq | Tablet 15 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11989B | Upadacitinib | Rinvoq | Tablet 15 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11989B | Upadacitinib | Rinvoq | Tablet 15 mg | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
11989B | Upadacitinib | Rinvoq | Tablet 15 mg | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
12005W | Certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Continuing treatment | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
12013G | Certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
12013G | Certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
12027B | Certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Initial treatment - Initial 1 (New patient) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
12027B | Certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Initial treatment - Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
12027B | Certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
12028C | Certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Continuing treatment | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
12040Q | Certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
12040Q | Certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
12063X | Certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial treatment - Initial 1 (New patient) | null | false | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
12063X | Certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial treatment - Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
12063X | Certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
12083Y | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient weighing at least 30 kg) | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
12083Y | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months in a patient weighing at least 30 kg) | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
12083Y | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months in a patient weighing at least 30 kg) | null | true | AUTHORITY_REQUIRED | Any | 4,429 | 2,025 | APRIL |
12084B | Tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Continuing treatment in a patient weighing at least 30 kg | 14088 | true | STREAMLINED | Any | 4,429 | 2,025 | APRIL |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.